Novo Nordisk Recalls Insulin Pens Due to Filling Foul-Ups

Danish drugmaker Novo Nordisk is recalling 33 batches of an insulin product in more than a dozen EU countries after a quality review uncovered filling foul-ups that could impact treatment. The recall affects certain batches of prefilled NovoMix 30 FlexPen (biphasic insulin aspart 30) 100U/ml products and the NovoMix 30 Penfill cartridges, both used in the treatment of diabetes.
Drug GMP Report